Drug intelligence / Profile preview

AEX-24

Development stage: Preclinical
Lead developer: Aexon Labs
Modality: Small Molecules
Administration: Oral

Overview

AEX-24 is a small molecule dual agonist of the Sigma-1 receptor (S1R) and Orexin 2 receptor (OX2R) currently in preclinical development by Aexon Labs. The Sigma-1 receptor is an endoplasmic reticulum-resident chaperone protein involved in calcium signaling and proteostasis, often targeted for neuroprotection. The Orexin 2 receptor plays a critical role in regulating the sleep-wake cycle and arousal. By targeting both pathways, AEX-24 aims to address complex neurological pathologies, although specific clinical indications have not yet been disclosed by the developer.

Other names: AEX-24AEX24AEX 24

Targets

TMBIM4 (BAX inhibitor motif-containing protein 4)HCRTR1 (Orexin/hypocretin receptor type 1)HCRTR2 (Orexin/hypocretin receptor type 2)CTSD (Cathepsin D)SIGMAR1 (Sigma non-opioid intracellular receptor 1)

Beyond the preview

Go deeper on AEX-24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AEX-24.

Explore the full profile